Nina Shah, MD

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Ola Landgren, MD, PhD, leads the discussion on the use of cilta-cel and ide-cel in newly diagnosed multiple myeloma and the sequencing of available therapies in transplant-eligible and transplant-ineligible patients.

Experts discuss emerging BCMA-targeting CAR T-cell therapies under investigation for treating multiple myeloma and barriers to CAR T access.

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Sagar Lonial, MD, reviews key takeaways from the DREAMM-2 trial, and Katja Weisel, MD, comments on the potential use of belantamab mafodotin in the early relapse setting for multiple myeloma.

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.

Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.

Ola Landgren, MD, PhD, reviews the results and clinical implications of the IKEMA study for patients with relapsed/refractory multiple myeloma.

Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.

Ola Landgren, MD, PhD; Sagar Lonial, MD; and Joshua Richter, MD, review current available treatment options and factors to consider when selecting therapy for patients with multiple myeloma who experience a first relapse.

Katja Weisel, MD, and Joshua Richter, MD, define biochemical vs clinical relapses in multiple myeloma and share recommendations for initiating treatment at either stage.

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

OncLive® speaks with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

Nina Shah, MD, discusses key findings from the phase 2 KarMMA trial in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Nina Shah, MD, discusses the clinical implications of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Nina Shah, MD, discusses the clinical significance of idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.